|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Castellsagué X, Díaz M, de Sanjosé S, et
al: Worldwide human papillomavirus etiology of cervical
adenocarcinoma and its cofactors: implications for screening and
prevention. J Natl Cancer Inst. 98:303–315. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hildesheim A and Wang SS: Host and viral
genetics and risk of cervical cancer: a review. Virus Res.
89:229–240. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Du CX and Wang Y: Expression of P-Akt,
NFkappaB and their correlation with human papillomavirus infection
in cervical carcinoma. Eur J Gynaecol Oncol. 33:274–277.
2012.PubMed/NCBI
|
|
5
|
Castellsagué X: Natural history and
epidemiology of HPV infection and cervical cancer. Gynecol Oncol.
110(Suppl 2): S4–S7. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schwarz JK, Payton JE, Rashmi R, et al:
Pathway-specific analysis of gene expression data identifies the
PI3K/Akt pathway as a novel therapeutic target in cervical cancer.
Clin Cancer Res. 18:1464–1471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Molinari F and Frattini M: Functions and
regulation of the PTEN gene in colorectal cancer. Front Oncol.
3:3262014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang S and Yu D: PI(3)king apart PTEN’s
role in cancer. Clin Cancer Res. 16:4325–4330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qi Q, Ling Y, Zhu M, et al: Promoter
region methylation and loss of protein expression of PTEN and
significance in cervical cancer. Biomed Rep. 2:653–658.
2014.PubMed/NCBI
|
|
10
|
Inui M, Martello G and Piccolo S: MicroRNA
control of signal transduction. Nat Rev Mol Cell Biol. 11:252–263.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ventura A and Jacks T: MicroRNAs and
cancer: short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartels CL and Tsongalis GJ: MicroRNAs:
novel biomarkers for human cancer. Clin Chem. 55:623–631. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao JJ, Yang J, Lin J, et al:
Identification of miRNAs associated with tumorigenesis of
retinoblastoma by miRNA microarray analysis. Childs Nerv Syst.
25:13–20. 2009. View Article : Google Scholar
|
|
14
|
Kwak SY, Yang JS, Kim BY, Bae IH and Han
YH: Ionizing radiation-inducible miR-494 promotes glioma cell
invasion through EGFR stabilization by targeting p190B rhoGAP.
Biochim Biophys Acta. 1843:508–516. 2014. View Article : Google Scholar
|
|
15
|
Yamanaka S, Campbell NR, An F, et al:
Coordinated effects of microRNA-494 induce G2/M arrest
in human cholangiocarcinoma. Cell Cycle. 11:2729–2738. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li X, Luo F, Li Q, et al: Identification
of new aberrantly expressed miRNAs in intestinal-type gastric
cancer and its clinical significance. Oncol Rep. 26:1431–1439.
2011.PubMed/NCBI
|
|
17
|
Olaru AV, Ghiaur G, Yamanaka S, et al:
MicroRNA down-regulated in human cholangiocarcinoma control cell
cycle through multiple targets involved in the G1/S checkpoint.
Hepatology. 54:2089–2098. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun HB, Chen X, Ji H, et al: miR494 is an
independent prognostic factor and promotes cell migration and
invasion in colorectal cancer by directly targeting PTEN. Int J
Oncol. 45:2486–2494. 2014.PubMed/NCBI
|
|
19
|
Lui WO, Pourmand N, Patterson BK and Fire
A: Patterns of known and novel small RNAs in human cervical cancer.
Cancer Res. 67:6031–6043. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee JW, Choi CH, Choi JJ, et al: Altered
microRNA expression in cervical carcinomas. Clin Cancer Res.
14:2535–2542. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
FIGO Committee on Gynecologic Oncology:
FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.
Int J Gynaecol Obstet. 125:97–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hou T, Ou J, Zhao X, Huang X, Huang Y and
Zhang Y: MicroRNA-196a promotes cervical cancer proliferation
through the regulation of FOXO1 and p27Kip1. Br J
Cancer. 110:1260–1268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
El-Mansi MT and Williams AR: Evaluation of
PTEN expression in cervical adenocarcinoma by tissue microarray.
Int J Gynecol Cancer. 16:1254–1260. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Y, Lai L, Chen Q, et al: MicroRNA-494
is required for the accumulation and functions of tumor-expanded
myeloid-derived suppressor cells via targeting of PTEN. J Immunol.
188:5500–5510. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang GW, Lin JH, Qian JP and Zhou J:
Identification of risk and prognostic factors for patients with
clonorchiasis-associated intrahepatic cholangiocarcinoma. Ann Surg
Oncol. 21:3628–3637. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu D, Qian J, Yin X, Xiao Q, Wang C and
Zeng Y: Expression of PTEN and survivin in cervical cancer:
promising biological markers for early diagnosis and prognostic
evaluation. Br J Biomed Sci. 69:143–146. 2012.
|
|
27
|
Leung CO, Deng W, Ye TM, et al: miR-135a
leads to cervical cancer cell transformation through regulation of
β-catenin via a SIAH1-dependent ubiquitin proteosomal pathway.
Carcinogenesis. 35:1931–1940. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang N, Zhou Y, Zheng L and Li H: MiR-31
is an independent prognostic factor and functions as an oncomir in
cervical cancer via targeting ARID1A. Gynecol Oncol. 134:129–137.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lao G, Liu P, Wu Q, et al: Mir-155
promotes cervical cancer cell proliferation through suppression of
its target gene LKB1. Tumour Biol. 35:11933–11938. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen J, Yao D, Zhao S, et al: MiR-1246
promotes SiHa cervical cancer cell proliferation, invasion, and
migration through suppression of its target gene thrombospondin 2.
Arch Gynecol Obstet. 290:725–732. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wen SY, Lin Y, Yu YQ, et al: miR-506 acts
as a tumor suppressor by directly targeting the hedgehog pathway
transcription factor Gli3 in human cervical cancer. Oncogene. Mar
10–2014.Epub ahead of print. View Article : Google Scholar
|
|
32
|
Wang L, Chang L, Li Z, et al: miR-99a and
-99b inhibit cervical cancer cell proliferation and invasion by
targeting mTOR signaling pathway. Med Oncol. 31:9342014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liang X, Liu Y, Zeng L, et al: miR-101
inhibits the G1-to-S phase transition of cervical cancer cells by
targeting Fos. Int J Gynecol Cancer. 24:1165–1172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu L, Jiang Y, Zhang H, Greenlee AR and
Han Z: Overexpressed miR-494 down-regulates PTEN gene expression in
cells transformed by
anti-benzo(a)pyrene-trans-7,8-dihydro-diol-9,10-epoxide. Life Sci.
86:192–198. 2010. View Article : Google Scholar
|
|
35
|
Lim L, Balakrishnan A, Huskey N, et al:
MicroRNA-494 within an oncogenic microRNA megacluster regulates
G1/S transition in liver tumorigenesis through
suppression of mutated in colorectal cancer. Hepatology.
59:202–215. 2014. View Article : Google Scholar :
|
|
36
|
Romano G, Acunzo M, Garofalo M, et al:
MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced
apoptosis in non-small-cell lung cancer through BIM
down-regulation. Proc Natl Acad Sci USA. 109:16570–16575. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ohdaira H, Sekiguchi M, Miyata K and
Yoshida K: MicroRNA-494 suppresses cell proliferation and induces
senescence in A549 lung cancer cells. Cell Prolif. 45:32–38. 2012.
View Article : Google Scholar
|
|
38
|
Shen PF, Chen XQ, Liao YC, et al:
MicroRNA-494-3p targets CXCR4 to suppress the proliferation,
invasion, and migration of prostate cancer. Prostate. 74:756–767.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Correia NC, Gírio A, Antunes I, Martins LR
and Barata JT: The multiple layers of non-genetic regulation of
PTEN tumour suppressor activity. Eur J Cancer. 50:216–225. 2014.
View Article : Google Scholar
|
|
40
|
Hafsi S, Pezzino FM, Candido S, et al:
Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of
drug-resistance (Review). Int J Oncol. 40:639–644. 2012.
|
|
41
|
Mulholland DJ, Kobayashi N, Ruscetti M, et
al: Pten loss and RAS/MAPK activation cooperate to promote EMT and
metastasis initiated from prostate cancer stem/progenitor cells.
Cancer Res. 72:1878–1889. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Choi BH, Pagano M and Dai W: Plk1 protein
phosphorylates phosphatase and tensin homolog (PTEN) and regulates
its mitotic activity during the cell cycle. J Biol Chem.
289:14066–14074. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Vogt PK, Gymnopoulos M and Hart JR: PI
3-kinase and cancer: changing accents. Curr Opin Genet Dev.
19:12–17. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Stewart AL, Mhashilkar AM, Yang XH, et al:
PI3 kinase blockade by Ad-PTEN inhibits invasion and induces
apoptosis in RGP and metastatic melanoma cells. Mol Med. 8:451–461.
2002.PubMed/NCBI
|
|
45
|
Tamura M, Gu J, Matsumoto K, Aota S,
Parsons R and Yamada KM: Inhibition of cell migration, spreading,
and focal adhesions by tumor suppressor PTEN. Science.
280:1614–1617. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Loures LF, Cândido EB, Vidigal PV, Seabra
MA, Marco LA and Silva-Filho AL: PTEN expression in patients with
carcinoma of the cervix and its association with p53, Ki-67 and
CD31. Rev Bras Ginecol Obstet. 36:205–210. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Vázquez-Ulloa E, Lizano M, Aviléss-Salas
A, Alfaro-Moreno E and Contreras-Paredes A: Abnormal distribution
of hDlg and PTEN in premalignant lesions and invasive cervical
cancer. Gynecol Oncol. 122:663–668. 2011. View Article : Google Scholar : PubMed/NCBI
|
